What are ADC's

Our services

ADC Review
is made possible by:

NCT00460447 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation (NCT00460447)

Trial Description
Study Design:

Prospective phase II trial with 30 patients in 1 site

Treatment Scheme:

  • Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after hematopoetic stem cell transplantation gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories; an antibody-drug conjugate) 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabine (Fludara®; Genzyme, Inc. ) 30 mg/ m² day –6 to –3 TBI 2×2 Gy day –3 to –2 (total dose 8 Gy) tacrolimus (Protopic®; Astellas Pharma Inc.) (level adapted) from day –3 on mycophenolate Mofetil (CellCept®; Genentech, Inc.) 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0
  • Option 2: Patient > 60 years of age or younger patients < 12 Months after hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m² day –3 to –1 TBI 1×2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day –3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0

This trial is sponsored by University Hospital Carl Gustav Carus. [1]

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 23, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar